About OligoVale
Built for a disease that has waited too long.
OligoVale is a focused biotechnology company working to bring the first treatment to people living with autosomal dominant leukodystrophy.
Our story
One disease. One genetic driver. A focused path forward.
ADLD is a fatal, ultra-rare neurological disease with no approved treatment. Its rarity has limited attention and investment, but its underlying biology points to a clear therapeutic strategy.
OligoVale was created to carry that strategy forward. We are building the focused capabilities and evidence needed to translate deep disease knowledge into a potential one-time therapy.
Our purpose
Bring the first treatment to people living with ADLD.
Our work starts with the patient community and stays grounded in the biology of the disease. We believe focus, scientific rigor, and responsible development can create a meaningful path for an ultra-rare condition.
From the ADLD Center
Rooted in the community and the science.
OligoVale was spun out of the ADLD Center, which licenses the program and supports patient research. That origin keeps the company connected to the people, questions, and scientific insight that shaped the therapeutic approach.
Patient-centered
The needs of people living with ADLD define the purpose of the work.
Science-led
A known genetic driver gives the program a precise biological foundation.
Deliberately focused
A small company structure keeps attention on the evidence needed to move forward.
Connect with OligoVale.
For partnering, scientific, community, or general inquiries, we would be glad to hear from you.